JPH0972902A - Element for analyzing whole blood - Google Patents
Element for analyzing whole bloodInfo
- Publication number
- JPH0972902A JPH0972902A JP26459495A JP26459495A JPH0972902A JP H0972902 A JPH0972902 A JP H0972902A JP 26459495 A JP26459495 A JP 26459495A JP 26459495 A JP26459495 A JP 26459495A JP H0972902 A JPH0972902 A JP H0972902A
- Authority
- JP
- Japan
- Prior art keywords
- whole blood
- red blood
- blood cells
- water
- polyoxyethylene sorbitan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 26
- 239000008280 blood Substances 0.000 title claims abstract description 26
- 239000002245 particle Substances 0.000 claims abstract description 16
- 229920001214 Polysorbate 60 Polymers 0.000 claims abstract description 6
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 6
- 239000004094 surface-active agent Substances 0.000 claims abstract description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 238000004458 analytical method Methods 0.000 claims description 14
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 7
- 238000004132 cross linking Methods 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 abstract description 28
- 238000000034 method Methods 0.000 abstract description 10
- 239000007788 liquid Substances 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 2
- 239000012528 membrane Substances 0.000 description 11
- 239000011148 porous material Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- -1 polyethylene terephthalate Polymers 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000012466 permeate Substances 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CDGBQMHYFARRCC-UHFFFAOYSA-N 3-(n-ethyl-3,5-dimethylanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC(C)=CC(C)=C1 CDGBQMHYFARRCC-UHFFFAOYSA-N 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 241001191009 Gymnomyza Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NWADXBLMWHFGGU-UHFFFAOYSA-N dodecanoic anhydride Chemical compound CCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCC NWADXBLMWHFGGU-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- ZPIRTVJRHUMMOI-UHFFFAOYSA-N octoxybenzene Chemical compound CCCCCCCCOC1=CC=CC=C1 ZPIRTVJRHUMMOI-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- HLXGRHNZZSMNRX-UHFFFAOYSA-M sodium;3-(n-ethyl-3,5-dimethylanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC(C)=CC(C)=C1 HLXGRHNZZSMNRX-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】 本発明は、全血を試料と
し、血漿中に含まれる特定成分を分析するための分析用
要素に関する。TECHNICAL FIELD The present invention relates to an analytical element for analyzing a specific component contained in plasma using whole blood as a sample.
【０００２】[0002]
【従来の技術】 患者の医学的な診断を行う上で、血液
中のグルコースやコレステロールといった物質の濃度を
分析することは重要な意味を持っている。血液中のこれ
らの物質の濃度を分析する際には、正確な分析操作を行
うために、赤血球を測定系から除去しなければならな
い。2. Description of the Related Art Analyzing the concentration of substances such as glucose and cholesterol in blood is important for making a medical diagnosis of a patient. When analyzing the concentrations of these substances in blood, red blood cells must be removed from the measurement system in order to perform accurate analytical operations.
【０００３】一般的には、遠心分離によって全血から赤
血球を除去した血清又は血漿が分析試料として用いられ
る。Generally, serum or plasma obtained by removing red blood cells from whole blood by centrifugation is used as an analytical sample.
【０００４】しかしながら、赤血球を除去するためには
専用の装置とそれを操作する労力と時間が必要となるこ
とから、全血をそのまま測定試料として用いることが望
ましい。特に、家庭において患者自らが測定する際に有
効となる。However, it is desirable to use whole blood as it is as a measurement sample because a dedicated device and labor and time for operating the device are required to remove red blood cells. In particular, it is effective when the patient himself / herself measures at home.
【０００５】赤血球を除去するための専用の装置を用い
ず全血から赤血球を除去する方法としては、例えば、特
開平１−７２０６５には、繊維含有濾過層に赤血球を吸
着させる方法が開示されている。As a method for removing red blood cells from whole blood without using a dedicated device for removing red blood cells, for example, JP-A-1-72065 discloses a method of adsorbing red blood cells on a fiber-containing filter layer. There is.
【０００６】また、特開昭４９−３３８００には、赤血
球が透過できない耐水性の膜を用いて除去する方法が、
開示されている。Further, Japanese Patent Laid-Open No. 49-33800 discloses a method of removing a red blood cell by using a water-resistant membrane which is impermeable.
It is disclosed.
【０００７】また、特開平２−１５０７５１には、水不
溶性の粒子で形成された膜によって赤血球を除去する方
法が開示されている。Further, Japanese Patent Application Laid-Open No. 2-150751 discloses a method of removing red blood cells by a membrane formed of water-insoluble particles.
【０００８】これらの方法のうち膜を用いて赤血球を除
去する方法の場合には、液体浸透性であり、かつ赤血球
不浸透性となる孔を有することが条件と言える。従っ
て、膜の孔径は、赤血球の大きさよりも小さくなくては
ならない。Among these methods, the method of removing red blood cells using a membrane requires that it has pores that are liquid-permeable and are impermeable to red blood cells. Therefore, the pore size of the membrane must be smaller than the size of red blood cells.
【０００９】赤血球の大きさは、直径が約８．５μｍ、
厚さが約２．４μｍなので、膜の孔径は、１μｍ以下が
よい。The size of red blood cells is about 8.5 μm in diameter,
Since the thickness is about 2.4 μm, the pore size of the membrane is preferably 1 μm or less.
【００１０】一方、水不溶性の粒子で形成された膜によ
って赤血球を除去する方法では、水不溶性の粒子の粒径
が不均一であるために、大きな粒子の間に小さな粒子が
入り込み、孔径の小さい緻密な膜が形成されることにな
る。On the other hand, in the method of removing red blood cells by a membrane formed of water-insoluble particles, since the water-insoluble particles are non-uniform in size, small particles enter between large particles and the pore size is small. A dense film will be formed.
【００１１】しかし、これらの膜の孔径が小さくなる
と、液体成分が膜を浸透する速度が遅くなる。液体成分
が膜を浸透する速度が遅くなると、試薬層の上部と下部
で反応開始に不均一さを生じ、いつまでも反応が終了し
ないといった不都合が生じる。However, when the pore size of these membranes becomes smaller, the rate at which the liquid component permeates the membrane becomes slower. If the rate at which the liquid component permeates the membrane becomes slow, the reaction start will be non-uniform in the upper and lower parts of the reagent layer, and the reaction will not end indefinitely.
【００１２】また、試料として全血を用いると、膜の孔
が赤血球によってふさがれ液体成分が浸透する速度がさ
らに遅くなる現象が生じる。従って、液体の浸透性は、
孔径の他に、全血中の赤血球の量によっても、影響され
る。When whole blood is used as a sample, a phenomenon occurs in which the pores of the membrane are blocked by red blood cells and the liquid component permeates further slowly. Therefore, the permeability of the liquid is
Besides the pore size, it is also affected by the amount of red blood cells in whole blood.
【００１３】ところが、全血中の赤血球の量は、個人ま
たはそのときの生理状態によって異なる。このことは、
試料として全血を用いた時に、個人またはそのときの生
理状態によっても、液体成分の浸透する量が変化する現
象を引き起こす。However, the amount of red blood cells in whole blood varies depending on the individual or the physiological condition at that time. This means
When whole blood is used as a sample, the phenomenon in which the amount of the liquid component permeates changes depending on the individual or the physiological state at that time.
【００１４】[0014]
【発明が解決しようとする課題】これまで述べたよう
に、分析する血液中の赤血球の量によって、液体成分の
浸透する量は変化する。この現象は、正確な分析結果を
得ることを妨げることになる。As described above, the permeation amount of the liquid component changes depending on the amount of red blood cells in the blood to be analyzed. This phenomenon hinders obtaining accurate analysis results.
【００１５】[0015]
【課題を解決するための手段】発明者らは、上記課題を
解決するため、鋭意研究を重ねた結果、以下のような発
明をするに至った。Means for Solving the Problems The inventors have conducted intensive studies in order to solve the above problems, and as a result, have made the following inventions.
【００１６】すなわち、全血を試料とし、血漿中の特定
成分を分析するための分析用要素であって、該分析用要
素が支持体と該支持体上に固着した試薬層からなり、該
試薬層において、 （ｉ）水不溶性の粒子 （ｉｉ）水不溶性の粒子を架橋するための架橋剤 （ｉｉｉ）ポリオキシエチレンソルビタン系の界面活性
剤 を含むことを特徴とすることで、意外なことにも、全血
中の赤血球の量によって分析結果が変化しないことを発
見した。That is, an analysis element for analyzing a specific component in plasma by using whole blood as a sample, wherein the analysis element comprises a support and a reagent layer fixed on the support, Surprisingly, the layer is characterized by containing (i) water-insoluble particles (ii) crosslinking agent for crosslinking water-insoluble particles (iii) polyoxyethylene sorbitan-based surfactant Also found that the analysis results did not change depending on the amount of red blood cells in whole blood.
【００１７】[0017]
【発明の実施の形態】本発明において使用するポリオキ
シエチレンソルビタン系の界面活性剤には、ポリオキシ
エチレンソルビタンモノラウレート、ポリオキシエチレ
ンソルビタンモノオレイトなどがあるが、ポリオキシエ
チレンソルビタンモノラウレートを用いるのが好まし
い。BEST MODE FOR CARRYING OUT THE INVENTION Polyoxyethylene sorbitan-based surfactants used in the present invention include polyoxyethylene sorbitan monolaurate and polyoxyethylene sorbitan monooleate. It is preferred to use rates.
【００１８】水不溶性の粒子は、赤血球を通さず液体を
透過させる機能を持たせることが可能なものであればよ
いが、望ましくは光を効率よく反射できるものがよい。
例えば、二酸化チタン、硫酸バリウム、酸化亜鉛、酸化
マグネシウムなどを用いることができるが、白色度が高
い二酸化チタンが好ましい。The water-insoluble particles may be any particles as long as they have a function of allowing a liquid to pass therethrough without allowing red blood cells to pass through them, but preferably those capable of efficiently reflecting light.
For example, titanium dioxide, barium sulfate, zinc oxide, magnesium oxide and the like can be used, but titanium dioxide having high whiteness is preferable.
【００１９】水不溶性の粒子の架橋剤としては、ヒドロ
キシプロピルセルロース、アルギン酸ナトリウム、ポリ
ビニルアルコール、ポリビニルピロリドン、ポリプロピ
オン酸ビニル共重合体（商品名：プロピオファン（ＢＡ
ＳＦ製））など、又はその組合せを用いることができる
が、ヒドロキシプロピルセルロース、ポリプロピオン酸
ビニル共重合体、又はその組合せが好ましい。As a crosslinking agent for water-insoluble particles, hydroxypropyl cellulose, sodium alginate, polyvinyl alcohol, polyvinylpyrrolidone, vinyl polypropionate copolymer (trade name: propiophane (BA
(Manufactured by SF)) or the like, or a combination thereof can be used, but hydroxypropyl cellulose, a vinyl polypropionate copolymer, or a combination thereof is preferable.
【００２０】膜の形成法は、水不溶性の粒子、水不溶性
の粒子の架橋剤、溶媒と測定対象中の成分を分析可能な
試薬とを適当な量だけ混合することで試薬溶液を作製し
た後に、この試薬溶液を支持体の上に一般的な方法によ
って塗工したりすることで作製できる。The method for forming a membrane is to prepare a reagent solution by mixing water-insoluble particles, a crosslinking agent for water-insoluble particles, a solvent and a reagent capable of analyzing the component in the measurement object in an appropriate amount. It can be prepared by coating this reagent solution on a support by a general method.
【００２１】ここにおける溶媒は、被分析対象物を測定
するための試薬に悪影響を及ぼさないものであればなん
でも良い。例えば水、メタノール、エタノールなどを用
いることができる。Any solvent may be used as long as it does not adversely affect the reagent for measuring the substance to be analyzed. For example, water, methanol, ethanol or the like can be used.
【００２２】この形成法に関しては、すでに特開平２−
１５０７５１に開示されており、公知と言える。This forming method has already been disclosed in JP-A-2-
It is disclosed in 150751 and can be said to be publicly known.
【００２３】この時用いる支持体としては、どのような
ものでもよいが、望ましくは、寸法安定性がよく、試薬
溶液をはじかないもので、乾燥した時に試薬が剥離しな
いものが良い。Any support may be used as the support at this time, but it is desirable that the support has good dimensional stability, does not repel the reagent solution, and does not peel off the reagent when dried.
【００２４】赤血球の色を排除するため下部から測光す
る場合は、光透過性の材質が望ましいが、反応に酸素が
必要な場合、酸素供給層として、多孔性フィルムを用い
ることも有用である。When photometry is performed from the bottom to eliminate the color of red blood cells, a light-transmissive material is preferable, but when oxygen is required for the reaction, it is also useful to use a porous film as the oxygen supply layer.
【００２５】例えば、使用可能な材質としては、ポリエ
チレンテレフタレート、ポリプロピレン、ポリカーボネ
ート、ニトロセルロース、ポリスチレン、ポリテトラフ
ロロエチレンなどがあげられ、ニュークリポア（ニュー
クリポア製）、サイクロポア（ワットマン製）、セルガ
ード（ヘキスト製）などの多孔性フィルムを含めて多く
のものが商品として販売されている。Examples of usable materials include polyethylene terephthalate, polypropylene, polycarbonate, nitrocellulose, polystyrene, polytetrafluoroethylene, and the like. Many products are sold as commercial products, including porous films such as manufactured products).
【００２６】[0026]
【実施例１】 グルコース分析用要素 下記の試薬を秤量し、充分撹拌混合して試薬液を調製し
た。この試薬液を、厚さ１０μｍのニュークリポアの上
に１００μｍの厚さに塗工し、４０℃で１時間乾燥さ
せ、１ｃｍ×１ｃｍに裁断した。これを試薬液塗工面を
上にして、中央に直径４ｍｍの貫通孔のあいた２ｃｍ×
２ｃｍポリエチレンテレフタレートフィルムを下部より
張り付けて、分析用要素を得た。 試薬の組成 グルコースオキシダーゼ（東洋紡） ２０ＫＵ パーオキシダーゼ（東洋紡） ２０ＫＵ ４−アミノアンチピリン（キシダ化学） １００ｍｇ Ｎ−エチル−Ｎ−（２−ヒドロキシ−３−スルホプロピル） −３，５−ジメチルアニリン ２００ｍｇ （略名：ＭＡＯＳ（同仁化学研究所）） ポリオキシエチレンソルビタンモノラウレート １００ｍｇ （商品名：Ｔｗｅｅｎ２０（ナカライテスク）） ヒドロキシプロピルセルロース（信越化学） １００ｍｇ 二酸化チタン（和光純薬） ５００ｍｇ リン酸緩衝液（０．１ｍｏｌ／ｌ、ｐＨ７．０） １０ｍｌ 試薬液塗工面を上にした分析用要素に、グルコース濃度
が１００ｍｇ／ｄｌの全血を、試薬液塗工面に４０μｌ
滴下し、１分後に支持体の貫通孔を通して下部（多孔性
フィルム側）から、積分球式反射率計にて、６４０ｎｍ
における反射率を測定した。得られた反射率を所定の検
量線によってグルコースの濃度に換算した。Example 1 Element for Glucose Analysis The following reagents were weighed and thoroughly mixed with stirring to prepare a reagent solution. This reagent solution was applied on a 10 μm-thick Nuclepore to a thickness of 100 μm, dried at 40 ° C. for 1 hour, and cut into 1 cm × 1 cm. This is 2 cm × with a through hole of 4 mm diameter in the center with the surface coated with the reagent solution facing up.
A 2 cm polyethylene terephthalate film was attached from the bottom to obtain an element for analysis. Composition of reagents Glucose oxidase (TOYOBO) 20KU Peroxidase (TOYOBO) 20KU 4-Aminoantipyrine (Kishida chemistry) 100mg N-Ethyl-N- (2-hydroxy-3-sulfopropyl) -3,5-dimethylaniline 200mg (Omitted) Name: MAOS (Dojindo Laboratories)) Polyoxyethylene sorbitan monolaurate 100 mg (Trade name: Tween20 (Nacalai Tesque)) Hydroxypropyl cellulose (Shin-Etsu Chemical) 100 mg Titanium dioxide (Wako Pure Chemical Industries) 500 mg Phosphate buffer (0) 0.1 ml / l, pH 7.0) 10 ml Whole blood with a glucose concentration of 100 mg / dl was placed on the analytical element with the reagent solution coated surface facing upward, and 40 μl on the reagent solution coated surface.
Dropping, 1 minute later, through the through-hole of the support, from the lower part (porous film side), using an integrating sphere type reflectometer, 640 nm
The reflectivity at was measured. The obtained reflectance was converted into glucose concentration by a predetermined calibration curve.
【００２７】[0027]
【実施例２】実施例１のポリオキシエチレンソルビタン
モノラウレートをポリオキシエチレンソルビタンモノオ
レイト（ナカライテスク）に変更して分析用要素を作製
し、分析を行い測定値を得た。Example 2 The polyoxyethylene sorbitan monolaurate of Example 1 was changed to polyoxyethylene sorbitan monooleate (Nacalai Tesque) to prepare an element for analysis, and analysis was performed to obtain a measured value.
【００２８】[0028]
【対象例１】実施例１のポリオキシエチレンソルビタン
モノラウレートをポリオキシエチレン（１０）オクチル
フェニルエーテル（和光純薬）に変更して分析用要素を
作製し、分析を行い測定値を得た。[Target Example 1] The polyoxyethylene sorbitan monolaurate of Example 1 was changed to polyoxyethylene (10) octyl phenyl ether (Wako Pure Chemical Industries, Ltd.) to prepare an element for analysis, and analysis was performed to obtain a measured value. .
【００２９】[0029]
【対象例２】実施例１のポリオキシエチレンソルビタン
モノラウレートをポリオキシエチレン（２３）ラウロイ
ルエーテル（和光純薬）に変更して分析用要素を作製
し、分析を行い測定値を得た。[Target Example 2] The polyoxyethylene sorbitan monolaurate of Example 1 was changed to polyoxyethylene (23) lauroyl ether (Wako Pure Chemical Industries, Ltd.) to prepare an element for analysis, and analysis was performed to obtain a measured value.
【００３０】実施例１、実施例２、対象例１、対象例２
の結果を表１に示す。実施例は対象例に比較して明らか
に赤血球量の影響を受けなくなっている。特に実施例１
において顕著に観察される。Example 1, Example 2, Target Example 1, Target Example 2
The results are shown in Table 1. The examples are clearly less affected by the amount of red blood cells as compared with the control examples. In particular, Example 1
Are noticeably observed in.
【００３１】[0031]
【表１】 [Table 1]
【００３２】[0032]
【発明の効果】全血中の赤血球を除去し、その中の特定
成分を分析するための分析用要素において、水不溶性の
粒子、その架橋剤、およびポリオキシエチレンソルビタ
ン系の界面活性剤を含むことで、分析結果が変化しな
い。これによって、全血を試料として血液中の特定成分
を分析する際に、試料によって異なる赤血球量の影響を
受けることなく正しく血液中の特定成分の量、濃度を分
析することが可能となった。また、全血中の赤血球の量
による測定値の変化の受けにくい、血液中の特定成分の
量、濃度を正しく分析できる全血分析用要素を作製する
ことが、可能となった。EFFECT OF THE INVENTION An analytical element for removing red blood cells in whole blood and analyzing a specific component therein, comprising water-insoluble particles, a cross-linking agent thereof, and a polyoxyethylene sorbitan-based surfactant. Therefore, the analysis result does not change. As a result, when a specific component in blood is analyzed using whole blood as a sample, it is possible to accurately analyze the amount and concentration of the specific component in blood without being affected by the amount of red blood cells which differs depending on the sample. Further, it has become possible to produce an element for whole blood analysis, which is less susceptible to changes in measured values due to the amount of red blood cells in whole blood, and which can accurately analyze the amount and concentration of a specific component in blood.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 山口 武広 京都府京都市南区東九条西明田町57番地 株式会社京都第一科学内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Takehiro Yamaguchi 57 Kyoto Higashikujo Nishiamita-cho, Minami-ku, Kyoto City Kyoto Prefecture Daiichi Kagaku Co., Ltd.
Claims (2)
析するための分析用要素であって、該分析用要素が支持
体と該支持体上に固着した試薬層からなり、該試薬層に
おいて、 （ｉ）水不溶性の粒子 （ｉｉ）水不溶性の粒子を架橋するための架橋剤 （ｉｉｉ）ポリオキシエチレンソルビタン系の界面活性
剤 を含むことを特徴とする分析用要素。1. An analytical element for analyzing a specific component in plasma using whole blood as a sample, the analytical element comprising a support and a reagent layer fixed on the support. An element for analysis characterized in that the layer contains (i) water-insoluble particles, (ii) a crosslinking agent for crosslinking the water-insoluble particles, and (iii) a polyoxyethylenesorbitan-based surfactant.
面活性剤が、ポリオキシエチレンソルビタンモノラウレ
ートである請求項１に記載の分析用要素。2. The analytical element according to claim 1, wherein the polyoxyethylene sorbitan-based surfactant is polyoxyethylene sorbitan monolaurate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP26459495A JP3584255B2 (en) | 1995-09-06 | 1995-09-06 | Elements for whole blood analysis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP26459495A JP3584255B2 (en) | 1995-09-06 | 1995-09-06 | Elements for whole blood analysis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0972902A true JPH0972902A (en) | 1997-03-18 |
| JP3584255B2 JP3584255B2 (en) | 2004-11-04 |
Family
ID=17405479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP26459495A Expired - Fee Related JP3584255B2 (en) | 1995-09-06 | 1995-09-06 | Elements for whole blood analysis |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3584255B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002073203A1 (en) * | 2001-03-09 | 2002-09-19 | Mitsubishi Kagaku Iatron, Inc. | Method of measuring whole blood |
-
1995
- 1995-09-06 JP JP26459495A patent/JP3584255B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002073203A1 (en) * | 2001-03-09 | 2002-09-19 | Mitsubishi Kagaku Iatron, Inc. | Method of measuring whole blood |
| US7338809B2 (en) | 2001-03-09 | 2008-03-04 | Mitsubishi Kagaku Iatron, Inc. | Method for assaying whole blood |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3584255B2 (en) | 2004-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4312834A (en) | Diagnostic agent for the detection of component materials in liquid and process for producing same | |
| CA2133983C (en) | Test article and method for performing blood coagulation assays | |
| US7323315B2 (en) | Method for reducing effect of hematocrit on measurement of an analyte in whole blood | |
| JPH0623745B2 (en) | Test apparatus and method for component detection of liquid samples | |
| JPH03163361A (en) | Blood separation and detection of assay product | |
| JPH0743374B2 (en) | Whole blood test method | |
| JPH0219908B2 (en) | ||
| JP2665640B2 (en) | Measurement method using dry analytical element and dry analytical element | |
| JP2004239906A (en) | Method and test piece for determining glucose in blood | |
| JPH0726960B2 (en) | Dry whole blood analysis element | |
| JP2611890B2 (en) | Measurement method using dry analytical element and dry analytical element | |
| JPH0688816A (en) | Asymmetrical sandwich film system as diagnostic test device | |
| JPH09105750A (en) | Measuring method corrected in hematocrit value | |
| JP3584255B2 (en) | Elements for whole blood analysis | |
| US7955563B2 (en) | Methods for applying reactive films containing solids to microporous membranes and membranes produced therefrom | |
| WO1988009824A1 (en) | Improvements in diagnostic test strips | |
| JPH0526875A (en) | One-piece type multilayer analysis element | |
| JPS6371653A (en) | Whole blood diluting liquid | |
| JPH07191020A (en) | Method for analyzing whole-blood sample using whole-blood analyzing element | |
| JP3147560B2 (en) | Multi-item analysis method | |
| JPH0219905B2 (en) | ||
| JPH0682444A (en) | Power-free portable incubator | |
| JP2006275716A (en) | Test paper | |
| JPH02179450A (en) | Testing tool | |
| JPH05322887A (en) | Whole-blood analyzing element and measuring method using it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040609 |
|
| A61 | First payment of annual fees (during grant procedure) |
Effective date: 20040623 Free format text: JAPANESE INTERMEDIATE CODE: A61 |
|
| R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 4 Free format text: PAYMENT UNTIL: 20080813 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080813 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090813 Year of fee payment: 5 |
|
| LAPS | Cancellation because of no payment of annual fees |